Reuters logo
3 个月前
BRIEF-Lantheus and GE Healthcare announce the signing of a definitive license agreement for worldwide development and commercialization of Flurpiridaz F 18
2017年4月25日 / 中午12点26分 / 3 个月前

BRIEF-Lantheus and GE Healthcare announce the signing of a definitive license agreement for worldwide development and commercialization of Flurpiridaz F 18

1 分钟阅读

April 25 (Reuters) - General Electric Co

* Lantheus and GE Healthcare announce the signing of a definitive license agreement for worldwide development and commercialization of Flurpiridaz F 18

* Lantheus Holdings - Under the agreement, GE Healthcare will lead and fund development program of Flurpiridaz F18, including second phase III clinical study

* Lantheus Holdings says it will receive $5 million upfront cash payment and, if successful, up to $60 million in regulatory and sales milestones payments Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below